Cultural Change: Impact as cultural change- for whom and how?

Over the last decade many academic and practitioner efforts have been made to introduce “impact” into local, national and international science policy agendas. There are many different ways in which such agendas are being introduced, but often they require changes in management processes and culture. The nature of these changes also differs across countries. In this session we propose to focus on how different approaches to the impact agenda alter the role of the different stakeholders in the science policy process: scientists, policy-makers, the assessment agencies, and the users and beneficiaries of research results (like patients in the case of health sciences). Accelerating, promoting and enhancing impact is, for instance, involving shifts in the governance of research programs, with the introduction of “real time impact assessment” tools and the consequent change in evaluation culture. This session will bring together a diversity of angles and initiatives, with the ultimate goal of inspiring mutual learning, as we explore who the “impact agenda” is – or is not – working for.
RGB Logo
novo_nordisk_fonden_419px (1)

Takes Place

Friday 26 February | 2pm

Theme Moderator and Speaker

paula_adam

Paula Adam

Paula Adam (PhD) is an expert in research impact assessment from the perspective of public policy, implementation and change management. Since 2010, she works at the Agency for Health Quality and Assessment (AQuAS https://aquas.gencat.cat/ca/ambits/recerca-salut/) of the Government of Catalonia. In 2013, she co-funded together with Jonathan Grant and Kathryn Graham ‘The International School on Research Impact Assessment’ (ISRIA). This school trained a few hundreds of science practitioners from all over the globe during 5 years. She led a testimonial of this experience in co-authorship with Pavel V Ovseiko and others through the publication of an ISRIA Statement. In her carrier, she has payed special focus on the assessment of biomedical research centers and the key performance indicators in collaboration with the ‘Instituto de Salud Carlos III’ from the Spanish Government. Over the past years, Paula has gained expertise on gender policies in science and the promotion of professional and public involvement in research. She also has a long-standing experience on public policy analysis and evaluation (at the OECD in Paris). She obtained her PhD from the European University Institute in Florence, Italy in 1996.

Speakers

Screenshot 2021-02-16 at 12.28.03

Adam Kamenetzky

Adam Kamenetzky is a Senior Research Fellow at NIHR’s Central Commissioning Facility. His work applies social research methods to improve NIHR’s capacity to learn about the wider value of its £1 billion+ investments in health and care research. With colleagues across NIHR, he is developing a programme of ‘research on research’, staff training and capacity-building to help NIHR better understand, support and evidence impact.

Before joining NIHR, Adam worked as a research fellow at the Policy Institute at King’s College London, conducting research into science policy and organisational approaches to research impact and evaluation. Adam is at the early stages of a practice-oriented PhD in research impact and assessment and holds an MSc in Science Communication and BSc in Developmental Biology.

Screenshot 2021-02-16 at 12.28.43

Jordi Molas-Gallart

Jordi Molas-Gallart is Research Professor at the Spanish National Research Council (CSIC), Director of INGENIO (CSIC-UPV), a joint research centre of CSIC and the Polytechnic University of Valencia, and Visiting Fellow at SPRU (University of Sussex) where he obtained his PhD and worked for some 15 years as a researcher and Senior Lecturer. His research interests focus mainly on science and technology policy evaluation and impact assessment. He has led and contributed to many research projects for a wide variety of organisations, including the UK Medical Research Council (MRC), INSERM, the European Commission, and the Russell Group of British universities among others. He was editor of Research Evaluation, a journal published by Oxford University Press between 2013 and 2020, and President of the European Network of Indicator Designers (ENID) between 2015 and 2019. He has contributed to many European Commission expert groups, and chaired the Science Europe working group on Research Policy and Programme Evaluation.

Screenshot 2021-02-16 at 12.40.03

Dr Rafael Simó

Dr. Rafael Simó is the Chair of the Division of Endocrinology and Nutrition at Vall d’Hebron University Hospital, Director of Diabetes and Metabolism Research Unit at Vall d’Hebron Research Institute (VHIR), Professor of Medicine & Endocrinology at the Autonomous University of Barcelona and Deputy Director of Clinical Research at VHIR. His group belongs to CIBERDEM (the Spanish network for the research of diabetes and associated metabolic diseases) and he is also principal investigator of RECAVA (Spanish network for the research of cardiovascular diseases).

Prof. Simó has authored over 300 articles related to diabetes which have been published in high-profile peer-reviewed journals, besides 14 book chapters. He has participated in 26 research projects related to diabetic retinopathy and in 34 projects related to clinical diabetes. He has been the Coordinator of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). This consortium (constituted by 19 partners all of them leaders in diabetic retinopathy from 8 different countries) has been funded by the EC for developing the first clinical trial using neuroprotective agents topically administered to prevent or arrest the development of diabetic retinopathy. In addition, he is the current coordinator of the “Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk of dementia (RECOGNISED). This consortium has also been funded by the EC and consist of 21 partners (including EATRIS and 3 SMEs) from 9 different countries.

Prof. Simó is the Diabetologist of Expert Committee on Diabetic Retinopathy and Vascular Diseases of the EVICR.net (European Vision Clinical Research) and the current President of the European Association for the Study of Diabetes-Eye complications (EASD-ec). He is renowned worldwide for his contributions to the pathophysiology of diabetic complications, in particular diabetic retinopathy. Prof. Simó received the Spanish Society of Diabetes Award (Rodríguez Miñón Award-2008) for a career in the field of Clinical Research in Diabetes, the “Dr. Josep Trueta” Award of the Academy of Medical Sciences from Catalonia (2011) for his innovative contributions in Biomedicine, and the Award of the Spanish Society of Endocrinology (2015) for the development and consolidation of a high-quality research group.

Screenshot 2021-02-16 at 12.40.47

Derek C Stewart

Derek C Stewart, patient advocate for involvement in research mainly in the United Kingdom. Hon Professor at NUI Galway, Ireland.

Born too many years ago in Ayr, Scotland, Derek was treated successfully for throat cancer in 1995.  A former teacher he became actively involved in numerous aspects of patient involvement and advocacy at a local and national level, being the founder Chair of the Consumer Liaison Group for the National Cancer Research Institute.

Derek was Associate Director for the National Institute for Health Research – Clinical Research Network (NIHR CRN) for nine years up until 2017. He is a Member of Cancer Research UK.

Currently, Derek is involved with a number of research projects mainly to do with the Trials Methodology Research including Evidence Synthesis Ireland.

Blog: https://wordpress.com/home/involveddotblog.wordpress.com

Twitter: @DerekCStewart